within Pharmacolibrary.Drugs.ATC.G;

model G04CB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.13499999999999998,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Finasteride is a synthetic 4-azasteroid and a competitive inhibitor of type II 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used primarily for the treatment of benign prostatic hyperplasia (BPH) in men and male pattern hair loss (androgenetic alopecia). Finasteride is an FDA-approved, widely used oral medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult male volunteers following single oral administration.</p><h4>References</h4><ol><li>Aditya K Gupta, Mesbah Talukder, Greg Williams,Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.,The Journal of dermatological treatment,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35920739/'>https://pubmed.ncbi.nlm.nih.gov/35920739/</a></li><li>A K Gupta, M Venkataraman, M Talukder, M A Bamimore,Finasteride for hair loss: a review.,The Journal of dermatological treatment,2022<a href='https://pubmed.ncbi.nlm.nih.gov/34291720/'>https://pubmed.ncbi.nlm.nih.gov/34291720/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G04CB01;
